Польшина Наталья Ивановна
Moscow Clinical Scientific Center · 26 works · 11 citations · h-index 2
Top works
- Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study
- Interim results analysis of the PERFECTION observational study in patients with metastatic non-small cell lung cancer
- Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
- Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
- 284P Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease
- Comparative analysis of activity of cytochrome isoenzyme P450 C YP2C9 in elderly and senile patients and with that in healthy volunteers of the first period of middle age
- Characteristics of the functional state of peripheral blood neutrophils in patients with luminal breast cancer
- THE ROLE OF ANTICHOLINERGIC PROPERTIES OF DRUGS IN THE DEVELOPMENT OF FALLS IN PATIENTS OF SENILE AGE
- Промежуточные результаты наблюдательного исследования PERFECTION в популяции пациентов с метастатическим немелкоклеточным раком легкого
- Immune-related adrenal insufficiency: A single center retrospective analysis.
- The combination of lenvatinib and pembrolizumab in the treatment of patients with metastatic kidney cancer and factors of poor prognosis: experience of clinics in Moscow: A prospective observational study
- Epidemiology, Predictors, and Impact of Endocrine Immune-Related Adverse Events on Outcomes in Patients with Malignant Tumors
- РОЛЬ ПРИМЕНЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ С АНТИХОЛИНЕРГИЧЕСКИМИ СВОЙСТВАМИ В РАЗВИТИИ ПАДЕНИЙ У ПАЦИЕНТОВ СТАРЧЕСКОГО ВОЗРАСТА
- Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia
- Редкие иммуноопосредованные нежелательные явления: клиническая характеристика, подходы к диагностике и лечению
- Эффективность и безопасность ленватиниба с пембролизумабом при распространенном почечноклеточном раке в реальной практике: обновленные данные российского наблюдательного исследования
- Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study
- Abstract PO4-20-09: Successful outcome of locally advanced HR+HER2+ breast cancer treatment in a young female after pancreas-kidney transplantation. 3-year follow-up
- Predictors of endocrine immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICI) in routine clinical practice.
- Cabozantinib (CABO) after prior immune checkpoint inhibitor (ICI) and tyrosine-kinase inhibitors (TKI) therapy in metastatic renal cell carcinoma (mRCC): Real-world evidence (RWE) from a Moscow observational program.